Johnson & Johnson (JNJ) on Tuesday announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint of clinical response, with 36.5% of patients treated with the highest dose achieving endoscopic improvement at Week 12.
At Week 12, patients treated with 400 mg of icotrokinra achieved a clinical response rate of 63.5% versus 27% for placebo, while response rates were 58.1% and 54.7% for patients treated with 200 mg and 100 mg doses, respectively.
Based on these results, the company has initiated the ICONIC-UC Phase 3 protocol in adults and adolescents with moderately to severely active UC and the ICONIC-CD Phase 2b/3 protocol in adults with moderately to severely active Crohn's disease.
Icotrokinra is also being evaluated in the pivotal Phase 3 ICONIC program in moderate-to-severe plaque psoriasis and in the ICONIC-PSA 1 and ICONIC-PSA 2 studies in active psoriatic arthritis.
A New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in July 2025 seeking the first approval of icotrokinra for the treatment of adults and pediatric patients 12 years of age and older with moderate to severe plaque psoriasis.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.